Treatment with SCD1 decreased ESCC cell ferroptosis and conferred radiation resistance by promoting the biosynthesis of oleic and palmitoleic acid, whereas the use of MF‐438, an SCD1 inhibitor, enhanced ferroptosis and immunogenic cell death in tumor cells, increasing the efficacy of radiotherapy in ESCC.[106] Of note, the expressions of SLC7A11 in ESCC tissues and NRF2 in the nucleus were directly related to the prognosis of patients with ESCC. The gene discussed is SLC7A11; the disease is neoplasm.